Compugen today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for COM503, initiating a Phase 1 trial of COM503, a potential first-in-class high-affinity anti-IL-18 binding protein (IL-18BP) antibody, which was licensed to Gilead Sciences last year for $60 million upfront plus up to $758 million in future milestone payments.
The approval of this IND triggered a $30 million milestone payment from Gilead Sciences.
Compugen's preclinical in vivo data showed that COM503 monotherapy demonstrated efficacy in breast cancer, colon cancer, and melanoma models. In the E0771 model, it showed better efficacy than PD-1 antibody, while the data from the other two models were moderate.
Currently, Compugen's core pipeline includes PVRIG antibodies, TIGIT antibodies, etc., and triple therapy with PD-1 is being carried out. In 2018, Compugen reached a collaboration with Bristol Myers Squibb to develop the combined administration potential of COM701 and Opdivo. The PD-1/TIGIT bispecific antibody Rilvegostomig, licensed to AstraZeneca, has advanced to Phase III clinical trials and completed the first patient dosing (FPI).About the COM503 Phase 1 Clinical Trial:This Phase 1 trial is a first-in-human dose-escalation and dose-expansion study designed to evaluate the safety and tolerability of COM503 as a monotherapy and in combination with Gilead’s anti-PD-1 drug zimberelimab in patients with advanced or metastatic solid tumors globally.Reference: Compugen Official WebsiteScan the WeChat QR code to add the editor of Antibody Circle.Those who meet the requirements can join the Antibody Circle WeChat group!Please indicate: Name + Research Direction!All articles reprinted by this official account are intended to convey more information, with the source and author clearly stated. Media or individuals who do not wish to be reprinted can contact us at (cbplib@163.com), and we will delete the content immediately. All articles represent the views of the author and do not represent the position of this site.
